Depot perphenazine decanoate and enanthate for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  David, Anthony ^a   Quraishi, Seema N ^a   Rathbone, John ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF MENTAL HEALTH   (United Kingdom)

Author keywords

Antipsychotic agents *therapeutic use ; Delayed action preparations; Humans; Perphenazine *analogs derivatives; therapeutic use ; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPENTHIXOL DECANOATE; NEUROLEPTIC AGENT; PERPHENAZINE DECANOATE; PERPHENAZINE ENANTHATE; PLACEBO;

BELGIUM; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; HUMAN; MOTOR DYSFUNCTION; NETHERLANDS; PORTUGAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77950152303     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001717.pub2     Document Type: Review

References (43)

1. Ahlfors 1980 {published data only} Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. Acta Psychiatrica Scandinavica 1980;61:77-91.
2. Eufe 1979 {published data only} Eufe R, Wegener G. Double blind compartive trial with 2 depot neuroleptics (perphenazine enanthate and fluphenthixol decanoate with chronic schizophrenia [Doppelblind vergleich von 2 depotneuroleptika (Perphenazin-onanthat und flupentixol-decaoat bei chronischer schizophrenie)]. Nervenarzt 1979;50:534-9.
3. Knudsen 1985c {published data only} Knudsen P, Hansen LB, Auken G, Waehrens J, Hojholdt K, Larsen NE. Perphenazine decanoate vs perphenazine enanthate efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatrica Scandinavica 1985;72(supp 322):15-28.
4. Tegeler 1979 {published data only} Tegeler J, Floru L. A comparative study of the longacting neuroleptics perphenazin enanthate and fluspirilene [Eine Vergleichende Untersuchung Der Depot-Neuroleptika Perphenazin Onanthat Und Fluspirilen]. Pharmakopsychiatrie Neuropsychopharmakologie 1979;12(5):357-65. [: EMBASE 1980018158]
5. Angst 1975 {published data only} Angst J, Woggon B. Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, fluspirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate. Arzneimittel Forschung 1975;25(2):267-70.
6. Bakke 1973 {published data only} Bakke O. Clinical experience with depot neuroleptics. Acta Psychiatrica Scandinavica 1973;246:32-46.
7. Dencker 1994 {published data only} Dencker SJ, Gios I, Martensson E, Norden T, Nyberg G, Persson R, Roman G, Stockman O, Svard KO. A long term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanaote in schizophrenic patients. Psychopharmacology 1994;114:24-30.
8. Giannelli {published data only} Giannelli A, Rabboni M, Zarattini F. Clinical profiles of action, individual treatment preferences, affects and contraindications of three depot neuroleptics compared in a multicentre trial [Profili clinici di azione, indicazioni preferenziali, effetti terapeutici e controindicazioni di tre neurolettici depot in trial multicentrico di confronto]. Rivista di Psichiatria 1990;25(1):7- 24.
9. Kistrup 1991 {published data only} Kistrup K, Gerlacj J, Aaes-Jorgensen T, Larsen N. Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients. Psychopharmacology 1991;105:42-8.
10. Knudsen 1985a {published data only} Knudsen P, Hansen LB, Hojholdt K, Larsen NE. Long-term depot neuroleptic treatment with perphenazine decanoate I. Acta Psychiatrica Scandinavica 1985;76(supp 322):29-40.
11. Knudsen P, Hansen LB, Hojholdt K, Larsen NE. Long-term depot neuroleptic treatment with perphenazine decanoate II. Acta Psychiatrica Scandinavica 1985;76(supp 322):40-50.
12. Kundsen 1985b {published data only} Knudsen P, Hansen LB, Larsen NE. Perphenazine decanoate in sesame oil vs perphenazine enanthate in sesame oil. Acta Psychiatrica Scandinavica 1985;76(supp 322):11-14.
13. Lindholm 1978 {published data only} Lindholm H, Gullberg BO, Ohman A, Sedvall G. Effects of perphenazine enanthate injections on rolactin levels in plasma from schizophrenic women and men. Psychopharmacology 1978;57:1-4.
14. Rapp 1972 {published data only} Rapp W. Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia. Pharmakopsychiatrie Neuro Psychopharmakologie 1972;5:205-14. [: EMBASE 1980018158]
15. Rapp 1986 {published data only} Rapp W, Hellbom E, Norrman O, Palm U, Rodhe K, Forsman A, Larsson M. A double blind crossover study comparing haloperidol decanoate and perphanazine enantate. Current Therapeutic Research 1986;39(5):665-70.
16. Rysanek 1982 {published data only} Rysanek R, Svestka J, Nahunek K, Ceskova E. Experience with perphenazine-enanthate in the maintenance therapy of schizophrenic psychoses. Activas Nervosa Superior (Praha) 1982;24(4):227-8.
17. Aaes-Jorgenson 1985 Aaes-Jorgenson A. Pharmacokinetics of oral and depot neuroleptics-Clinical relevance. Symposium Espo. 1 Feb 1985.
18. Alderson 2004 Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. The Cochrane Library 2004, Issue Issue 1. [: In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd]
19. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [: PDE020600]
20. Barnes 1994 Barnes TRE, Curson DA. Long term depot antipsychotics. A risk benefit assessment. Drug Safety 1994;10(6):464-79.
21. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
22. Curson 1995 Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the medical research council fluphenazine/placebo trial. British Journal of Psychiatry 1985;146:464-80.
23. David 1994 David AS, Cutting JC (eds). The neuropsychology of schizophrenia. Hove, E.Sussex: Lawrence Erlbaum Associates, 1994.
24. Davis 1986 Davis JM, Andriukatis S. The natural course of schizophrenia and effective maintenance drug therapy. Journal of Clinical Psychopharmacology 1986;6(suppl 1):2-10.
25. Dencker 1980 Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics?A depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica 1980;61(supp 279):64-76.
26. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
27. DoH 1996 Department of Health, NHS Executive. Burdens of disease: a discussion document. HMSO 1996.
28. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
29. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
30. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
31. Guy 1976 Guy W. In: National Institute of Mental Health, editor(s). ECDEU Assessment manual for psychopharmacology. Rockville, MD: DHEW publication No (ADM), 1976:124-585.
32. Haynes 1979 Haynes RB, Taylor WD, Sackett DL (Editors). Compliance in health care. Baltimore: John Hopkins University Press, 1979.
33. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
34. Hirsch 1973 Hirsch SR, Gaind R, Rohde PD. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial. British Medical Journal 1973;1:633-7.
35. Jablensky 1992 Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen ASO. Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study. Psychological Medicine (Monograph Supplement) 1992;20:1-97.
36. Kane 1998 Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, et al.Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropschopharmacology 1998;8:55-66.
37. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
38. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
39. Moher 2001 Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
40. Petersson 1971 Petersson H. Chronic schizophrenia treated with depot perphenazine. Nordic Journal of Psychiatry 1971;25(4):303-8.
41. Schulz 1994 Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:125-8.
42. Simon 1995 Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. Journal of Clinical Epidemiology 1995;48:363-73.
43. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.